[{"id":"3a138d15-6bca-4eff-8361-765e025c0dc8","acronym":"FORTITUDE-101","url":"https://clinicaltrials.gov/study/NCT05052801","created_at":"2021-09-22T11:53:35.151Z","updated_at":"2025-02-25T16:38:37.071Z","phase":"Phase 3","brief_title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","source_id_and_acronym":"NCT05052801 - FORTITUDE-101","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 03/07/2022","start_date":" 03/07/2022","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 08/18/2025","study_completion_date":" 08/18/2025","last_update_posted":"2025-02-07"},{"id":"e79a541e-0cd8-480b-90cf-f790043b9fc7","acronym":"FORTITUDE-102","url":"https://clinicaltrials.gov/study/NCT05111626","created_at":"2021-11-08T14:53:12.581Z","updated_at":"2024-07-02T16:34:59.979Z","phase":"Phase 3","brief_title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05111626 - FORTITUDE-102","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Recruiting","enrollment":" Enrollment 528","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 09/26/2026","primary_completion_date":" 09/26/2026","study_txt":" Completion: 09/26/2026","study_completion_date":" 09/26/2026","last_update_posted":"2024-05-30"},{"id":"7bdf22c5-b0e5-4dd7-ba06-b849bce2df96","acronym":"FORTITUDE-201","url":"https://clinicaltrials.gov/study/NCT05267470","created_at":"2022-03-04T15:53:35.624Z","updated_at":"2024-07-02T16:35:04.416Z","phase":"Phase 1","brief_title":"A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)","source_id_and_acronym":"NCT05267470 - FORTITUDE-201","lead_sponsor":"Amgen","biomarkers":" KRAS • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression","tags":["KRAS • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 04/09/2024","primary_completion_date":" 04/09/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2024-05-10"},{"id":"94fc3ab5-0532-4f36-b807-3064b8e380bd","acronym":"FIGHT","url":"https://clinicaltrials.gov/study/NCT03694522","created_at":"2021-01-17T17:12:46.809Z","updated_at":"2024-07-02T16:35:17.364Z","phase":"Phase 2","brief_title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT03694522 - FIGHT","lead_sponsor":"Five Prime Therapeutics, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Completed","enrollment":" Enrollment 155","initiation":"Initiation: 09/14/2018","start_date":" 09/14/2018","primary_txt":" Primary completion: 09/23/2020","primary_completion_date":" 09/23/2020","study_txt":" Completion: 05/13/2022","study_completion_date":" 05/13/2022","last_update_posted":"2024-02-28"},{"id":"ffefeeab-740a-45fc-871d-672db86f637b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913115","created_at":"2023-06-22T19:11:32.163Z","updated_at":"2024-07-02T16:35:45.005Z","phase":"Phase 1","brief_title":"A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer","source_id_and_acronym":"NCT05913115","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":"","alterations":" ","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bemarituzumab (AMG 552)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 06/12/2017","start_date":" 06/12/2017","primary_txt":" Primary completion: 06/19/2018","primary_completion_date":" 06/19/2018","study_txt":" Completion: 06/19/2018","study_completion_date":" 06/19/2018","last_update_posted":"2023-06-22"},{"id":"b6fe236f-69a1-4ca8-9bff-2776cafafed2","acronym":"PANGEA-IMBBP","url":"https://clinicaltrials.gov/study/NCT02213289","created_at":"2021-01-18T10:22:06.665Z","updated_at":"2024-07-02T16:36:32.164Z","phase":"Phase 2","brief_title":"PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression","source_id_and_acronym":"NCT02213289 - PANGEA-IMBBP","lead_sponsor":"University of Chicago","biomarkers":" EGFR • HER-2 • PD-1","pipe":" | ","alterations":" HER-2 amplification","tags":["EGFR • HER-2 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • bemarituzumab (AMG 552) • depatuxizumab (ABT-806)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 01/20/2015","start_date":" 01/20/2015","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 08/20/2020","study_completion_date":" 08/20/2020","last_update_posted":"2021-04-08"}]